72
Participants
Start Date
August 31, 2005
Primary Completion Date
July 31, 2008
Study Completion Date
August 31, 2008
Matuzumab
Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
Epirubicin
Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
Cisplatin
Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
Capecitabine
Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.
Research Site, Essen
Research Site, Hamburg
Research Site, Oldenburg
Research Site, Recklinghausen
Research Site, A Coruña
Research Site, Barcelona
Research Site, Cadiz
Research Site, Valencia
Research Site, Bern
Research Site, Geneva
Research Site, Lausanne
Research Site, Sankt Gallen
Research Site, Northwood
Research Site, Bournemouth
Research Site, Cambridge
Research Site, Chelmsford
Research Site, Guildford
Research Site, Leicester
Research Site, London
Research Site, Newcastle
Research Site, Northwood
Research Site, Portsmouth
Merck KGaA, Darmstadt, Germany
INDUSTRY